Prevalence and Severity of Pruritus and Quality of Life in Patients With Cutaneous T-Cell Lymphoma

被引:70
|
作者
Wright, Abigail [1 ]
Wijeratne, Aruni [1 ]
Hung, Tracy [1 ]
Gao, Wei [2 ]
Whittaker, Sean [1 ,2 ]
Morris, Steven [1 ]
Scarisbrick, Julia [1 ]
Beynon, Teresa [1 ]
机构
[1] St Thomas Hosp, London SE1 7EH, England
[2] Kings Coll London, Kings Hlth Partners, London WC2R 2LS, England
关键词
Pruritus; itch; cutaneous T-cell lymphoma; CTCL; Skindex-29; quality of life; palliative care; MYCOSIS-FUNGOIDES; INTERNATIONAL-SOCIETY; PROGNOSTIC-FACTORS; SEZARY-SYNDROME; ORGANIZATION; SURVIVAL; PROPOSAL; OUTCOMES;
D O I
10.1016/j.jpainsymman.2012.01.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. Cutaneous T-cell lymphoma (CTCL), although rare, is associated with a significant symptom burden. Pruritus appears to be one of the most prominent and disturbing symptoms. Objectives. To describe the prevalence and severity of pruritus and quality of life (QOL) in patients with CTCL. Methods. Patients with CTCL able to complete two questionnaires were invited to complete a visual analogue scale for itch (VAS(itch)) and the Skindex-29. Prevalence of pruritus, mean score, and SD were estimated for the VAS(itch) and Skindex-29, and the Pearson's correlation coefficient was calculated to evaluate the relationship between severity of pruritus and QOL. Results. One hundred patients were recruited (mean [SD] age 57.9 [12.9] years, range 30-86 years). Eighty-eight percent reported pruritus in the preceding four weeks, 46% indicating that it was often or always a problem. The mean (SD) of VAS(itch) (n = 92) was 3.2 (3.2), range zero to 10. The mean (SD) total Skindex-29 score was 43.3 (27.7). More advanced disease stage was associated with poorer QOL. The Skindex-29 correlated strongly with the VAS(itch) (Pearson's correlation coefficient = 0.72, P < 0.001). Conclusion. All aspects of QOL are affected in CTCL. Pruritus is a common and troublesome symptom. A more advanced disease stage and more severe pruritus symptoms were associated with poorer QOL in this study. J Pain Symptom Manage 2013;45:114-119. (C) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 50 条
  • [31] An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma
    Man Hu
    Jörg Scheffel
    Daniel Elieh-Ali-Komi
    Marcus Maurer
    Tomasz Hawro
    Martin Metz
    Clinical and Experimental Medicine, 2023, 23 : 4177 - 4197
  • [32] Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma
    Lewis, D. J.
    Huang, S.
    Duvic, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (10) : 1652 - 1656
  • [33] Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma
    Booken, N.
    Heck, M.
    Nicolay, J. P.
    Klemke, C. D.
    Goerdt, S.
    Utikal, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (03) : 665 - 667
  • [34] Health-related quality of life and economic burden in Chinese patients with cutaneous T-cell lymphoma
    Wang, Yang
    Sun, Jianfang
    Sun, Huiping
    Zhang, Mingzhi
    Li, Zhiming
    Zhao, Haifeng
    Xie, Linna
    Huang, Wenrong
    Yan, Xiaojing
    Du, Xiwen
    Li, Xiaojiao
    Jin, Hui
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Gender disparities in health-related quality of life (HRQoL) in patients with cutaneous T-cell lymphoma
    Chalaka, C. W.
    Hippe, D. S.
    Shinohara, M. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S55 - S55
  • [36] What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus
    Georgia Biazus Soares
    Joan Guitart
    Gil Yosipovitch
    American Journal of Clinical Dermatology, 2024, 25 : 67 - 77
  • [37] CUTANEOUS T-CELL LYMPHOMA AND PRURITUS: THE ROLE OF IL-31 IN THE SKIN
    Nattkemper, Leigh
    Singer, Elisha
    Rook, Alain
    Yosipovitch, Gil
    ACTA DERMATO-VENEREOLOGICA, 2013, 93 (05) : 615 - 615
  • [38] Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®)
    Duvic, M
    Kuzel, T
    Olsen, EA
    Martin, AG
    Foss, FM
    Kim, YH
    Heald, PW
    Bacha, P
    Nichols, J
    Liepa, A
    CLINICAL LYMPHOMA, 2002, 2 (04): : 222 - 228
  • [39] Multiple dominant T-cell clones and increased disease severity in cutaneous T-cell lymphoma
    Sun, T.
    Martinez-Escala, E.
    Gao, J.
    Rosen, S.
    Guitart, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (08) : S2 - S2
  • [40] Health-related quality of life and economic implications of cutaneous T-cell lymphoma
    Semenov, Y. R.
    Rosenberg, A. R.
    Herbosa, C.
    Mehta-Shah, N.
    Musiek, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 190 - 196